Trial Profile
A study evaluating antibody-mediated neutralization and antibody-dependent cellular cytotoxicity responses in HIV-positive individuals under dolutegravir-based antiretroviral therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Aug 2017
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Elvitegravir
- Indications HIV-1 infections
- Focus Therapeutic Use
- 30 Aug 2017 New trial record
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science